Summary of Key Points
2026 is being hailed by the industry as the "Year One" for brain-computer interfaces, marking a crucial leap from laboratory research to clinical applications. Implantable brain-computer interfaces have entered the phase of registered clinical trials, and there will be a surge in commercialization over the next three years; non-invasive approaches are opening up new possibilities in the field of rehabilitation medicine. China is among the global leaders in certain technical aspects, but it must be cautious about homogenization and implantation safety risks. The industry needs to address fundamental questions such as "what to produce" and "who will pay for it." While capital is interested, there is a focus on precise targeting and compliance, with clinical value serving as the core driver for the industry's sustainable development.
1. 2026: The Year of Clinical Breakthroughs
The reason 2026 is considered the "Year One" for brain-computer interfaces is that implantable products have finally crossed the threshold from the laboratory to clinical use, officially entering the stage of nationally recognized clinical trials (GCP registration), which is like obtaining a ticket to enter the market.
- Implantable devices target three types of patients: BrainHug Technology's products are designed for people with mobility issues (paralysis), speech disorders (aphasia), and vision impairments (blindness). These products will see a surge in commercialization over the next three years. Stepwise medical approaches have already initiated large-scale invasive clinical trials, and their technology platforms (electrodes, chips, software, etc.) can be applied in various scenarios, with potential expansion into consumer healthcare (such as home devices) within the next 5-8 years.
- Advances in non-invasive rehabilitation: Traditional rehabilitation involves passive training (doctors assist patients), but brain-computer interfaces bring it to a "2.0 era" where the brain sends out signals of desire to move, and devices then trigger bodily movements, providing feedback back to the brain, creating an active closed-loop training system that is more efficient and engaging for patients.
2. Commercialization Path: From Hospitals to Homes
After clinical breakthroughs, the question of how to generate revenue becomes central. The experts suggest focusing on unmet medical needs before expanding:
- Startups should take a cautious approach: JinNao Technology emphasizes focusing on practical solutions rather than pursuing excessive technical specifications (e.g., more channels do not necessarily mean better performance). They aim to develop a product for a specific condition (e.g., motor dysfunction) first and collaborate with top doctors who understand the patients' needs.
- Expansion from healthcare to consumer products: XiangYu Medical plans to move from hospitals (B2B) to home use (B2C), enabling ordinary people to receive rehabilitation at home. EY experts suggest that, with rehabilitation and mental health as the foundation, additional consumer-oriented applications (e.g., sleep assistance, attention training) will emerge.
- Who will pay? Health insurance is key: DeTong Capital points out that some products are already covered by health insurance for initial surgeries, and as more products get included, their accessibility will increase, potentially expanding the market significantly.
3. China's Advantages
China is on par with the world in this field but must avoid duplication and safety issues:
- Strong technical foundation and large patient base: Years of research and a large number of patients with functional disorders (e.g., paralysis, aphasia) provide valuable clinical data.
- Skilled engineers: Chinese engineers are adept at integrating components (electrodes, chips, software) efficiently.
However, challenges include homogenization (many companies producing similar products) and safety concerns (surgical risks, body rejection). Companies need to differentiate their offerings.
4. Capital Perspective
Investors are optimistic about brain-computer interfaces but require precision and compliance:
- Sustainable profitability: Companies must have sufficient cash reserves before achieving commercial success.
- Compliance and targeted applications: Investors prefer companies that can use their technology in multiple areas, reducing costs and enhancing competitiveness.
- Proven effectiveness: New technologies must first demonstrate safety and efficacy in real-world settings before being marketed.
5. Future Prospects
The experts have a clear vision for the next three years:
- Surge in implantable commercialization: Zhang Zichao predicts a large number of implantable products will be introduced, creating a robust market.
- Wider adoption of non-invasive methods: Zhao Huafeng believes non-invasive interfaces will make rehabilitation more accessible and beneficial for patients.
- Focus on clinical value: Wang Shouyan emphasizes the need to maintain rationality during rapid development, focusing on addressing patients' real needs and promoting integration of technology, industry, and finance.
In summary, brain-computer interfaces represent a long-term effort rather than a short sprint, requiring both rapid progress and adherence to safety and clinical effectiveness standards.